Etanercept Inhibits Pro-inflammatory Cytokines Expression in Titanium Particle-Stimulated Peritoneal Macrophages by Chen, Z et al.
Chen et al 
Trop J Pharm Res, June 2015; 14(6): 983  
 
Tropical Journal of Pharmaceutical Research June 2015; 14 (6): 983-987 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v14i6.7 
Original Research Article 
 
 
Etanercept Inhibits Pro-inflammatory Cytokines 
Expression in Titanium Particle-Stimulated Peritoneal 
Macrophages 
 
Zhirong Chen1, Liang Zhan1, Zhidong Lu1, Yi Ma2, Zhihui Gao1, Haohui Guo1, 
Long Pang1 and Qunhua Jin1*  
1Department of Orthopedics, General Hospital of Ningxia Medical University. Yinchuan City, 2Department of Pathology and 
Physiology, Ningxia Medical University. Yinchuan City, 750004, Ningxia, China 
 
*For correspondence: Email: jinqunhua@sina.com; Tel: 095-16743581; Fax: 0951-4082981 
 
Received: 29 October 2014        Revised accepted: 9 April 2015 
 
Abstract 
Purpose: To investigate the inhibitory role of Etanercept in pro-inflammatory cytokines such as TNF-α, 
IL-1β and IL-6 production in titanium (Ti) particle stimulated macrophages. 
Methods: Peritoneal macrophages were stimulated with 1 × 109 Ti particles and treated simultaneously 
with or without 10, 100, or 1000 ng/mL Etanercept. The levels of TNF-α, IL-1β and IL-6 in the culture 
supernatants were measured using ELISA. 
Results: Titanium particles could stimulate TNF-α, IL-1β and IL-6 secretion in peritoneal macrophages. 
Etanercept inhibited Ti particle-induced TNF-α release by 29.7 % at 10 ng/ml (19.19 ± 4.72 pg/mL, p < 
0.01), 49.3 % at 100 ng/mL (13.83 ± 3.72 pg/ml, p < 0.01) and 60.4 % at 1000 ng/mL (10.82 ± 3.87 
pg/mL, p < 0.001), IL-1β release by 5.23 % at 10 ng/mL (34.79 ± 7.83 pg/mL, p > 0.05), 21.06 % at 100 
ng/mL (28.98 ± 4.81 pg/mL, p < 0.01) and 29.83 % at 1000 ng/mL (25.76 ± 5.23 pg/ml, p < 0.001), and 
IL-6 release by 38.69 % at 10 ng/mL (256.8 ± 99.56 pg/mL, p < 0.01), by 42.13 % at 100 ng/mL (242.4 ± 
33.26 pg/mL, p < 0.01) and 53.4 % at 1000 ng/ml (195.2 ± 48.82 pg/mL, p < 0.001). 
Conclusion: Etanercept has potent ability to prevent wear debris–induced osteolysis and may be 
valuable as a therapeutic agent for the treatment of prosthetic loosening in humans. 
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Total joint arthroplasties is a widely used final 
treatment option in many cases to reduce pain, 
restore joint function and allow patients to return 
to normal living [1]. Wear debris, which is 
generated from all the components of the 
prosthetic joint surface, is widely recognized as 
the major cause of aseptic loosening [2,3]. Wear 
debris are phagocytosed by macrophages, 
resulting in the secretion of proinflammatory 
cytokines, such as tumor necrosis factor-α (TNF-
α), interleukin-1β (IL-1β) and IL-6 [4-6]. Among 
them, TNF-α is the pivotal cytokine involved in 
wear debris-induced osteolysis. Blockage of 
TNF-α activity inhibits both osteoclast 
differentiation and osteolysis induced by wear 
particles in the murine calvaria model [7,8]. Thus, 
TNF-α has been proved to be potential treatment 
target for wear debris induced osteolysis. 
 
Etanercept, which is a soluble fusion protein 
composed of the extracellular domains of type 2 
TNF receptor (p75) fused to the Fc region of a 
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IgG1, is a TNF-α antagonist that has been 
approved by U.S. F.D.A. for the treatment of 
rheumatoid, juvenile rheumatoid and psoriatic 
arthritis [9,10]. Recent clinical data have 
indicated that Etanercept also has beneficial 
effects on preventing bone erosions in 
rheumatoid arthritis and psoriasis [11,12]. Given 
the emerging evidence that TNF-α plays a similar 
and central pathogenetic role in prosthetic 
loosening and rheumatoid arthritis, we proposed 
that Etanercept has the ability to inhibit wear 
debris induced osteolysis. The objective of 
current study was to determine if Etanercept was 
capable of inhibiting pro-inflammatory cytokines 
such as TNF-α, IL-1β and IL-6 production in 




Animals and reagents 
 
BALB/c mice (6 – 8 weeks old) were purchased 
from laboratory animal center of Ningxia medical 
college (Ningxia, China) and maintained in a 
temperature controlled room with 12 h light /dark 
cycles with regular chow and water. The 
experimental procedures were approved by the 
Laboratory Animal Care Committee at Ningxia 
medical college. All animals received humane 
care according to the criteria outlined in the 
"Guide for the Care and Use of Laboratory 
Animals" prepared by the National Academy of 
Sciences and published by the National Institutes 
of Health (NIH publication 86 - 23 revised 1985). 
Etanercept (trade name Enbrel) was purchased 
from Amgen & Wyeth (Philadelphia, PA, USA). 
Titanium particles (Ti6Al4V alloy) were a gift from 
Zimmer (Warsaw, IN, USA). Mouse tumor 
necrosis factor-α (TNF-α), interleukin -1β (IL-1β) 
and interleukin-6 (IL-6) ELISA kit were from R&D 
Systems (Minneapolis, MN, USA). RPMI-1640, 
L-glutamine, penicillin, streptomycin, and fetal 
bovine serum (FBS) were from Gibco (Grand 
Island, NY, USA). Limulus assay kit was from 
Horseshoe Crab Reagent Manufactory (Xiamen, 
China). 
 
Mouse peritoneal macrophage culture 
 
Resident peritoneal macrophages were collected 
from mice as previously described [13]. Briefly, 
peritoneal macrophages were recovered by 
peritoneal lavage with 5 ml of cold RPMI-1640 
medium and isolated by centrifugation (1000 
rpm/min, 10 min). Cells (2 × 105) were plated on 
24-well tissue culture plates and cultured in 
RPMI 1640 medium containing 10 % FBS, 
penicillin (100 U/ml) and streptomycin (100 
U/mL) at 37 oC, 5 % CO2 for 12 h. The no 
adherent cells were removed, and the adherent 
cells were washed twice with RPMI-1640 
medium and used in experiments. 
 
Preparation of Ti particles 
 
Commercially pure Titanium (Ti) particles 
(Zimmer, Warsaw, USA) were sterilized by 
incubation in 25 % nitric acid at 70 oC for 1 h and 
then suspended in phosphate-buffered saline 
(PBS) at a concentration of 1 × 109 particles /ml 
[8]. Particle size was confirmed with a Coulter 
Channelizer (Beckman Coulter, Fullerton, CA, 
USA), which determined 95 % of the particles to 
be < 5 μm in diameter. 
 
Limulus amebocyte lysate assay 
 
For determination of endotoxin concentration in 
Ti particle suspension, limulus amebocyte lysate 
(LAL) assays were performed according to the 
manufacturer’s protocol. Briefly, Ti particles 
suspension serum samples were diluted 10 % 
(v/v) in LAL reagent water, and heated to 70 oC 
for 5 min to remove any nonspecific inhibition to 
the assay. Samples were incubated with equal 
volumes of LAL for 10 min at 37 oC and 
developed with equal volumes of substrate 
solution for 6 min. The absorbance of the assay 
plate was read at 405 nm using a micro plate 
reader (BioTek, Winooski, VT). Samples and 
standards were run in duplicate, and the 




Peritoneal macrophage at 1 × 105 cells/well were 
stimulated with 1 × 109 Ti particles and treated 
simultaneously with or without 10, 100, or 1000 
ng/mL Etanercept. After 18 h, culture 
supernatants were collected and centrifuged at 
1500 rpm for 5 min to remove the Ti particles and 
cells, the supernatants were collected, and the 
levels of TNF-α, IL-1β and IL-6 in the culture 
were measured using ELISA kits (R&D Systems, 





All data were analyzed by Student’s t test and 
were expressed as means ± SEM, differences 
were considered statistically significant when p < 
0.05. The significance levels are marked *p < 




It has been shown that particulate debris could 
stimulate the production of pro-inflammatory 
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cytokines such as TNF-α, IL-1β and IL-6 in 
macrophages [14,15]. We first determined the 
effect of Ti particles that induces TNF-α, IL-1β 
and IL-6 release in resident peritoneal 
macrophages. Limulus assay has been 
performed and data showed that the Ti particle 
suspension was free of endotoxin (< 0.25 
EU/mL). 1 × 109 Ti particles were then used to 
treat macrophages and TNF-α, IL-1β and IL-6 
production were measured by ELISA. Data 
showed that TNF-α (9.48 ± 1.58 pg/mL vs. 27.3 ± 
4.47 pg /mL, p < 0.001), IL-1β (24.25 ± 5.25 
pg/mL vs. 36.71 ± 7.57 pg/mL, p < 0.01) and IL-6 
(122.3 ± 37.78  pg/mL vs. 418.9 ± 31.98 pg/mL, 
p < 0.001) production was substantially induced 
by Ti particles (Fig. 1 A-C). To evaluate the 
inhibitory effect of Etanercept on Ti particle-
induced TNF-α, IL-1β and IL-6 release, 
peritoneal macrophages were treated with or 
without Etanercept (10, 100, or 1000 ng/mL) for 
18 h. Data showed that Etanercept significantly 
inhibited Ti particle-induced TNF-α release by 
29.7 % at 10 ng/mL (19.19 ± 4.72 pg/ml, p < 








Figure 1: Inhibitory effect of Etanercept on titanium 
particle-induced TNF-α, IL-1β and IL-6 release by 
macrophages. Peritoneal macrophage (1 × 105 
cells/well) were stimulated with 1 × 109 Ti particles and 
treated simultaneously with or without 10, 100, or 1000 
ng/mL Etanercept. After 18 h, culture supernatants 
were collected and centrifuged at 1500 rpm for 5 min 
to remove the Ti particles and cells, the supernatants 
were collected, and the levels of TNF-α (A), IL-1β (B) 
and IL-6 (C) in the culture were measured using 
ELISA kits. The data shown are representatives of 
three independent experiments. Data are shown as 
mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001) 
 
(13.83 ± 3.72 pg/mL, p < 0.01) and 60.4 % at 
1000 ng/mL (10.82 ± 3.87 pg/mL, p < 0.001) 
compared to the Ti particles stimulated control 
(27.3 ± 4.47 pg/mL) (Fig.1 A), and significantly 
inhibited Ti particle-induced IL-1β release by 
5.23 % at 10 ng/mL (34.79 ± 7.83 pg/mL, p > 
0.05), 21.06 % at 100 ng/mL (28.98 ± 4.81 
pg/mL, p < 0.01) and 29.83 % at 1000 ng/ml 
(25.76 ± 5.23 pg/mL, p < 0.001) compared to the 
Ti particles stimulated control (36.71 ± 7.57 
pg/mL) (Fig. 1B). Etanercept could also 
significantly inhibit Ti particle-induced IL-6 
release by 38.69 % at 10 ng/mL (256.8 ± 99.56 
pg/mL, p < 0.01), 42.13 % at 100 ng/mL (242.4 ± 
33.26 pg/mL, p < 0.01) and 53.4 % at 1000 
ng/mL (195.2 ± 48.82 pg/mL, p < 0.001) 
compared to the Ti particles stimulated control 
(418.9 ± 31.98 pg/mL) (Fig. 1C). These results 
demonstrate that Etanercept has a dose-
dependent inhibitory effect on Ti particle-induced 
pro-inflammatory cytokines such as TNF-α, IL-1β 




The major finding of this study is that Etanercept, 
a TNF-α antagonist, could dose-dependently 
inhibit the production of TNF-α, IL-1β and IL-6 by 
C 
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macrophages stimulated with Ti particles. TNF-α 
may be a dominant upstream event that has 
dramatic consequences on periprosthetic 
osteolysis, because blockade of TNF-α also 
reduces the secretion of IL-1β and IL-6, TNF-α 
acts as an autocrine/paracrine stimulator of 
additional TNF-α release. These results are 
consistent with our hypothesis that Etanercept 
can inhibit the pro-inflammatory cytokine 
cascade induced by Ti stimulation of 
macrophages. Similar results were recently 
published by other investigators examining the 
effects of Etanercept on wear debris induced 
osteolysis using macrophage cell lines [16]. 
Combined with previously reports, It suggests 
that TNF-α is critically involved in osteolysis and 
aseptic loosening and that soluble TNF-α 
inhibitors, such as Etanercept, may be useful as 
therapeutic agents for the treatment of prosthetic 
loosening. 
 
TNF-α expression has been studied extensively 
in response to various stimuli. In this study, we 
used Ti particles to stimulate a pro-inflammatory 
response in macrophage cultures in vitro. Ti 
particles are readily available and the majority of 
the particles are small enough to be 
phagocytosed by macrophages (< 10 μm in 
diameter) [17]. Meanwhile, numerous literatures 
have shown that Ti particles induce the same 
reaction as other types of implant wear debris 
[18].  
 
Macrophages play a crucial role in inflammatory 
bone disorder such as wear debris-induced 
aseptic loosening and are major sources of 
inflammatory mediators. Here we chose resident 
peritoneal macrophages, which have been widely 
used as a macrophage source in mice as the 
exposed cells. Previous studies of macrophage 
physiology customarily used macrophage cell 
lines such as RAW264.7 and J774 cells [19]. 
These cells, derived from pristane-elicited murine 
peritoneal macrophages transformed with 
Abelson leukemia virus, have been particularly 
valuable because of their ease of culture, rapid 
growth rate, and phenotypic resemblance to 
primary macrophages. However, these cell lines 
cannot fully mimic the phenotype of primary 
macrophages in vivo and the uptake efficiency of 
Ti particles by the peritoneal macrophages 
maybe higher than that of RAW264.7 cells.  
 
Although we have shown that Etanercept is able 
to prevent pro-inflammatory cytokines production 
by macrophages stimulated with wear debris, the 
precise mechanism by which Etanercept is 
involved in wear debris induced osteolysis 
remains unknown. As the first pro-inflammatory 
cytokine produced by macrophages in response 
to particles, TNF-α has been shown to control 
the release of other pro-inflammatory mediators 
such IL-1β and IL-6. One primary mechanism 
may be that, as soluble receptor of TNF, 
Etanercept can competitively bind to the TNF 
membrane receptor (mTNF-R) on the cell 
surface and block all signaling through the 
membrane bound TNF receptors, thus inhibiting 
osteoclastogenesis and osteoclast activity. 
Another important mechanism by which TNF-α 
contributes to the pathogenesis of aseptic 
loosening is its inhibitory effects on osteoblasts. 
Etanercept may inhibit osteoclastogenesis by 
down regulating the expression of 
osteoprotegerin ligand and M-CSF, IL-6 and 




In summary, the present study suggests that 
Etanercept inhibits Ti particle-induced TNF-α, IL-
1β and IL-6 release by macrophages, and 
therefore, may be a potential therapeutic agent 
for the prevention and/or treatment of osteolysis 
and loosening after TJA. Further investigations 
are required to examine the inhibitory effects of 
Etanercept on wear debris induced osteolysis in 
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